Hormone Replacement Therapy: A 2026 Guide
England dispensed about 13 million hormone replacement therapy items to 2.6 million identified patients in 2023/24, increases of 22% and 12% respectively from the previous year, according to the NHS Business Services Authority's HRT data. HRT is no longer a niche treatment discussed only in specialist clinics. It's now part of routine menopause care for many people, while the practical questions have become more complicated: tablets or patches, gel or spray, what happens when a pharmacy can't obtain a familiar product, and how HRT fits alongside modern weight-management treatments.
Table of Contents
- Understanding Hormone Replacement Therapy and Why It Matters
- Types of HRT and How They Are Delivered
- Benefits and Risks Based on Clinical Evidence
- Accessing HRT Through the NHS and Private Routes
- HRT and Weight Management Including GLP-1 Medications
- Supply Challenges and Continuity of Care
- Common Questions About Hormone Replacement Therapy
Understanding Hormone Replacement Therapy and Why It Matters
Hormone replacement therapy replaces hormones that the body is producing in lower or less predictable amounts. During perimenopause, oestrogen and progesterone can fluctuate considerably. After menopause, oestrogen levels remain lower. HRT aims to relieve symptoms caused or worsened by these changes, rather than “resetting” the body or stopping ageing.
People commonly discuss HRT in relation to menopause, but it may also be considered during perimenopause, when symptoms begin before periods have stopped completely. It can also form part of treatment for some people with hypogonadism, where the body doesn't produce enough sex hormones for their age or physiological needs. The right approach depends on symptoms, medical history, reproductive anatomy and personal preferences.
What symptoms can HRT help?
The strongest evidence is for vasomotor symptoms, meaning hot flushes and night sweats. NICE's review of 16 randomised controlled trials and 3 Cochrane reviews found that HRT consistently improved hot flushes, night sweats, sleep outcomes and quality of life compared with placebo (NICE evidence review).
HRT may also help when hormonal changes contribute to:
- Sleep disruption, particularly when night sweats repeatedly wake you.
- Vaginal dryness and discomfort, where local vaginal oestrogen may be considered separately or alongside systemic treatment.
- Mood changes, especially when they occur with other menopausal symptoms.
- Bone health concerns, because lower oestrogen can contribute to bone loss.
That doesn't make HRT a cure-all. It won't treat every cause of fatigue, anxiety, low mood, pain or weight change, and it isn't prescribed to prevent cardiovascular disease or dementia. NICE describes HRT as the most effective treatment for vasomotor symptoms, but advises that it should be prescribed within licensed doses and not used for cardiovascular disease or dementia prevention (NICE clinical discussion aid).
Why use has grown in the UK
HRT prescribing in primary care has risen substantially. A UK study of primary-care prescribing found that first HRT prescriptions increased from 5.01 per 1,000 person-years at risk in 2010 to 18.16 per 1,000 person-years at risk in 2021, with an average annual increase of 13.64% (UK primary-care prescribing study).
Those figures don't mean HRT is suitable for everyone. They show that more patients and clinicians are discussing symptoms openly and considering treatment as part of individualised care. The most useful consultation question isn't “Is HRT good or bad?” It's “What are my symptoms, what are my risks, and which formulation fits my circumstances?”
Types of HRT and How They Are Delivered
The first decision usually concerns which hormones you need. If you've had a total hysterectomy, an oestrogen-only regimen may be appropriate because there's no womb lining requiring protection. If you still have a womb, oestrogen is generally combined with a progestogen to reduce the risk of the lining becoming excessively thick.
The progestogen may be given as part of a combined product or separately. Don't assume that the same HRT plan suits everyone with similar symptoms, because route, dose, bleeding pattern, migraine history, clot risk, skin sensitivity and convenience all matter.
Choosing the delivery route
Oral tablets are familiar and straightforward, but oral oestrogen passes through the digestive system and is associated with increased venous thromboembolism risk. GOV.UK safety advice reports that the risk is higher with combined oestrogen-progestogen therapy than with oestrogen-only therapy, and that thrombotic events are more likely during the first year of use (GOV.UK HRT safety advice).
Transdermal HRT, delivered through patches, gels or sprays, avoids the first-pass route through the liver. It's increasingly central to UK prescribing conversations, particularly when clinicians are considering clot risk, dose adjustment or a patient's preference to avoid tablets. A patch may be convenient, while gel or spray can offer more control over application, although those formats require a consistent daily routine and care to prevent transfer to another person.
| Delivery Method | Key Advantages | Considerations | Typical Use Cases |
|---|---|---|---|
| Tablets | Familiar and simple to take | Oral route may be less suitable where clot risk is a concern | People who prefer an oral routine and have been assessed as suitable |
| Patches | Regular transdermal delivery and no daily tablet | Adhesive reactions, patch lifting and supply interruptions can matter | People seeking a transdermal option or steadier application |
| Gels | Flexible transdermal application | Requires regular application and drying time | People who want to adjust application within a prescribed plan |
| Sprays | Transdermal delivery without an adhesive patch | Needs consistent application and appropriate skin care | People who prefer a spray format |
Sequential and continuous combined regimens
A sequential regimen usually provides oestrogen continuously and adds progestogen for part of the cycle, commonly producing a predictable withdrawal bleed. A continuous combined regimen supplies both hormones continuously and aims to avoid regular withdrawal bleeding over time. Your clinician will consider whether you're still having periods, how long it has been since your last period and whether bleeding is expected.
Practical rule: The “best” format is the one that controls symptoms, protects the womb when needed, fits your health profile and is realistic for you to use consistently.
Benefits and Risks Based on Clinical Evidence
HRT improves hot flushes, night sweats, sleep and quality of life for many people with troublesome menopausal symptoms. It can also reduce bone loss while treatment continues. The useful question is not whether HRT is “safe” or “unsafe”, but which benefits matter to you and how the risks change with the formulation, dose, route and your medical history.
What the safety guidance says
Risk discussions can become muddled when tablets, patches, gels and sprays are treated as identical. Oral HRT is associated with an increased risk of venous thromboembolism, and the risk is higher with combined treatment than with oestrogen-only treatment. Transdermal options may be considered when clot risk is a concern, although your clinician still needs to assess your full history.
Breast cancer risk also needs an individual explanation. Combined HRT and oestrogen-only HRT are different treatments, and risk may vary with the formulation, duration of use, age, family history and personal medical history. A consultation should put those factors together rather than offer a misleading yes-or-no answer.
HRT is not a general medicine for preventing every condition linked with ageing. Its role is mainly symptom relief and, for some people, protection against bone loss during use. It should not be started or continued without reviewing whether its benefits still fit your circumstances.
A consultation is a risk assessment
Your clinician may ask about:
- Personal or family history of breast, ovarian or womb cancer.
- Previous blood clots, stroke, heart disease or liver disease.
- Migraine, blood pressure and unexplained vaginal bleeding.
- Whether you have a womb and whether you still have periods.
- Current medicines, including weight-management treatment.
These questions help determine whether oestrogen needs to be combined with a womb-protecting progestogen, and whether a transdermal or oral route is more suitable. They also create a safer plan if symptoms, bleeding or side effects change.
For background on hormone formats and vaginal hormone questions, Momotaro Apotheca's hormone guide may be useful. It does not replace a consultation or the information supplied with a prescribed medicine.
Weight concerns can overlap with menopause symptoms and changes in body composition. This discussion of HRT patches and weight gain may help separate possible treatment effects from issues requiring a dedicated weight-management plan, including review of any GLP-1 medicine.
Accessing HRT Through the NHS and Private Routes
For many people, a GP appointment remains the starting point. Bring a short record of symptoms, including hot flushes, disrupted sleep, mood changes, vaginal symptoms, period changes, migraines, previous clots and treatments already tried. A timeline helps the clinician see whether symptoms fit menopause or need assessment for another cause.
The NHS pathway
The consultation usually covers symptoms, medical and reproductive history, and your treatment preferences. If HRT is suitable, the clinician may discuss oestrogen-only or combined treatment, the delivery route, expected bleeding and the timing of review. Follow-up checks symptom control, side effects and bleeding, then allows the dose or formulation to be adjusted.
The route matters in practical terms. Tablets are one option, but patches, gels and sprays deliver oestrogen through the skin. A transdermal option may be considered where the clinician thinks it better fits your medical history. The choice also depends on availability, since supply problems can affect whether a familiar product remains in stock. Ask what alternatives are suitable if your prescription cannot be filled.
Prescription costs are part of the UK discussion. In January 2024, the government announced that 500,000 women in England had benefited from cheaper HRT since April 2023 through the HRT Prescription Prepayment Certificate. Eligible HRT prescriptions were covered by a flat annual fee of £19.30 (GOV.UK HRT prepayment announcement). Check current NHS prescription guidance because eligibility and arrangements may change.
Private care
Private menopause clinics may provide quicker appointments or clinicians with a particular interest in menopause care. Consultation and prescription charges are usually separate, while follow-up arrangements differ. Before booking, ask who prescribes, how records will be shared with your NHS GP, what monitoring is included and how urgent concerns will be managed.
Private care still requires a proper medical assessment. Be cautious about services promising one standard hormone plan, overlooking your history or suggesting that tests alone can select the right treatment.
Bring your medication list, previous diagnoses and a record of bleeding patterns. These details can affect the safest route and regimen.
NHS and private care can overlap with other treatment decisions. If you are asking whether Mounjaro may be available through NHS services, this guide to accessing Mounjaro on the NHS explains how clinical criteria and local arrangements affect access.
A short explanation of the consultation process can help before you book:
HRT and Weight Management Including GLP-1 Medications
Menopause-related weight concerns are common, but the explanation isn't just “low oestrogen causes weight gain”. Hormonal changes can affect fat distribution, sleep, appetite, activity levels and how easy it feels to maintain muscle. Stress, medication, age, thyroid disease and lifestyle also matter.
HRT isn't a weight-loss treatment. Some people find that symptom relief makes sleep, movement and eating patterns easier to manage, while others notice little change in weight. Starting HRT with the expectation of substantial fat loss can lead to disappointment and may distract from the separate assessment that weight concerns deserve.
Where GLP-1 medicines fit
GLP-1 medicines, including Mounjaro and Wegovy, are prescribed for weight management when a person meets the relevant clinical criteria. They work through appetite and food-intake pathways, so they address a different clinical problem from HRT. Some people may be prescribed both, but there isn't one universal combination that's right for everyone.
Your GP or prescribing clinician should know about every medicine you use. They can consider nausea, reduced appetite, hydration, constipation, gallbladder concerns, other medical conditions and whether changing appetite affects your ability to eat enough protein and maintain strength. HRT adjustments should also be based on symptom response and safety, not on the assumption that a GLP-1 medicine will alter hormone requirements.
Medication check: Keep HRT and weight-management reviews connected. Changes in bleeding, migraines, blood pressure, appetite, gastrointestinal symptoms or mood deserve a joined-up discussion.
A structured nutrition and activity plan remains important alongside any medicine. PlateBird's weight control resources offer general ideas that may help with meal planning, while your clinician should tailor advice to your health, medication and goals. For questions about using HRT with Mounjaro specifically, see this HRT and Mounjaro guide.
Trim is one UK option for medically supervised weight management. Its service uses a digital clinical assessment, clinician review, prescribed treatments where appropriate, nutrition guidance, strength-focused training and ongoing support. It isn't a replacement for menopause care, so patients using HRT should ensure their weight-management provider and GP understand the full treatment plan.
Supply Challenges and Continuity of Care
A prescription can be clinically appropriate and still be difficult to obtain. UK Parliament and NHS-linked guidance has documented shortages or discontinuations affecting specific HRT products, including Estradot patches, Indivina tablets and Tridestra. Serious shortage protocols have also permitted pharmacists to substitute equivalent estradiol patches in defined circumstances (UK Parliament written question on HRT supply).
That doesn't mean every HRT product is unavailable, or that a substitution is automatically identical in day-to-day use. Patch size, adhesive, application schedule and the prescribed oestradiol strength can differ. A switch may be clinically reasonable, but you should understand what has changed and how to use the replacement.
What to do when your usual product isn't available
Contact the pharmacy first and ask whether the problem affects the whole product, a particular strength or the current wholesaler. If the pharmacy can't dispense it, contact your GP practice before your supply runs out. Don't stop or ration doses without advice, particularly if symptoms return quickly or you use HRT for premature ovarian insufficiency or another specific indication.
Ask the prescriber to record the exact product, strength, route and directions. If a pharmacist offers an alternative under a shortage protocol, confirm the product and instructions before leaving. A different patch may need a different application schedule, and gel or spray requires separate handling guidance.
Planning for interruptions
Request repeat prescriptions with enough time for the pharmacy to identify stock problems, but don't accumulate medicines beyond what your prescriber authorises. Keep a note of the active ingredient and dose, not only the brand name. If you develop heavy or unexpected bleeding, severe chest pain, sudden breathlessness, a swollen painful leg or other urgent symptoms, seek prompt medical help rather than treating the issue as a supply problem.
Common Questions About Hormone Replacement Therapy
Can I start HRT during perimenopause?
Yes. HRT may be appropriate during perimenopause if symptoms are affecting daily life. You do not have to wait until periods stop. Your clinician will consider symptoms, cycle pattern, contraception needs and medical history. HRT is not contraception, and bleeding patterns can change after treatment starts.
How long is it safe to use HRT?
There is no single time limit for everyone. Review the decision as your symptoms, health and preferences change. Evidence discussed earlier found no difference in mortality between people using oestrogen-only or combined HRT and those not taking HRT. Individual risk assessment still matters, particularly when treatment is started or changed.
Does HRT affect cancer screening?
HRT does not replace breast, cervical or bowel screening. Attend appointments when invited, and report new breast changes, unusual bleeding or other concerning symptoms. A personal history of cancer or a strong family history may mean you need specialist advice before starting or altering treatment.
What happens if I stop HRT?
Symptoms can return, especially after stopping suddenly, although some people remain comfortable. Depending on your regimen and circumstances, your clinician may suggest reducing treatment gradually or stopping it directly. Vaginal symptoms can need separate local treatment even after systemic HRT has ended.
Are bioidentical hormones safer?
“Bioidentical” describes different products. Some regulated HRT medicines contain hormones chemically identical to those made by the body. Compounded preparations may have different licensing, quality controls and supporting evidence. Ask about the exact product, dose, route and evidence rather than judging safety from the label.
What if I'm worried about tablets?
Tell your prescriber what concerns you. Patches, gels and sprays deliver oestradiol through the skin, and may suit people who want to avoid tablets or have particular clot-risk considerations. The choice also depends on skin tolerance, convenience, availability and personal preference. UK prescribing has shifted towards transdermal options, but tablets are not automatically unsuitable for every patient.
A different product is not always used in exactly the same way. Check the prescribed strength, application instructions and whether any progestogen is also needed. If supply problems interrupt treatment, contact the pharmacy and GP practice rather than rationing doses.
HRT works best as an ongoing conversation. Before an appointment, note your main symptoms, treatment goals and concerns. Ask what improvement to expect, which side effects need attention and what to do if the prescribed product is unavailable.
Trim provides medically supervised UK weight-management care, including clinician assessment of options such as Mounjaro and Wegovy, alongside nutrition and strength-focused support. If menopause symptoms and weight concerns are both affecting you, visit Trim to explore whether its programme may suit you, and discuss your complete medication history with its clinical team.